Valneva IPO Presentation Deck slide image

Valneva IPO Presentation Deck

Chikungunya is a Significant, Growing Public Health Concern V A Mosquito-Borne Viral Outbreak Disease in Tropical /Sub-tropical Regions Can cause debilitating joint and muscle pain, fever, headache, nausea and rash, with potential serious, long-term health impairment¹ Currently there are no vaccines or effective treatments for chikungunya Global market, including endemic regions (see below), estimated to exceed $500 million annually by 2032² 2020 outbreaks³: The Americas (incl. Brazil, the Caribbean, Colombia, Costa Rica, Mexico), Asia (India, Malaysia, Thailand) and Africa (Congo, Kenya, Sudan) 'Valneva Chikungunya Factsheet. 2 VacZine Analytics Chikungunya virus vaccines Global demand analysis. February 2020. ECDC chikungunya worldwide overview. Valneva - Roadshow Presentation April 2021 17
View entire presentation